Introduction {#sec1-1}
============

In the West, the incidence of cataract in people over 50 years is 15%, while in developing countries it is about 40%.\[[@ref1]\] In the developing world, the prevalence is believed to be greater and the onset at earlier ages, making the social and medical costs of blindness from cataract highly disproportional in areas of the world that can ill afford them.\[[@ref2]\] Thus, senile cataract is a common and obvious ocular condition associated with dramatic effects upon vision. The World Health Report published in 1998\[[@ref3]\] estimated that there were 19.34 million people who are bilaterally blind from age-related cataract. This represented 43% of all blindness. Minassian and Mehra estimated that for India alone 3.8 million people become blind from cataract each year.\[[@ref4]\]

The similarity between *Timira* and Cataract starts from the word meaning itself. *Timira* is derived from word *Tim* which means *Kledane* that is imbibing of moisture, increase of watery substance in the eye.\[[@ref5]\] *Timira*/cataract denotes a shade of darkness which makes the view of the patients affected by this disease as if looking through water, moisture, waterfall, glazed paper, waxed paper etc.

Till date no accepted medical treatment is available for cataract, surgery is the only available treatment for cataract. Though the prevalence of cataract blindness would decrease due to increase in cataract surgery rate, the absolute number of cataract-blind would increase from 7.75 million in 2001 to 8.25 million in 2020 due to the substantial increase in the population above 50 years in India over this period.\[[@ref6]\] Data available in India show that all cataract surgeries are not sight-restoring.\[[@ref7]\] Surgical treatment of cataract imposes great economic burden on the society, and the backlog is perhaps too big to be handled by surgery alone at the same time surgical approach have its own complications. If such a factor is identified which simply delays the onset of cataract by a period of 10 years, the number of cataract surgeries would drastically decrease by 45% or more.\[[@ref8]\]

Therefore, the entire world is looking at the other systems of medicine to tackle the situation and looking upon preventive ophthalmology for improving and maintaining vision. In such a scenario, a study on Immature Cataract management gains much importance. Among many anti-cataract medicines *Elaneer Kuzhambu Anjana*\[[@ref9]\] is extensively used clinically since centuries in Kerala by local physicians, however, clinical and experimental data on the efficacy are not available on this formulation. Hence, this formulation was selected for the present study. As senile cataract can be taken as *Swabhava Balapravritta Vyadhi* which occurs as an aging change in the body. According to Ayurveda, a *Rasayana* drug which contains rejuvenating properties is the best drugs to avoid senile changes, so *Triphaladi Ghana Vati* was selected for this trial. This drug contains 11 Ayurvedic drugs; maximum among them were having *Rasayana* (rejuvenating) properties.

Therefore, this study was planned with the aim to assess the efficacy of *Triphaladi Ghana Vati* and *Elaneer Kuzhambu Anjana* as anti-cataract agents.

Materials and Methods {#sec1-2}
=====================

Total forty patients, from the outpatient department of Shalakya Tantra Department, Institute of Postgraduate Teaching and Research in Ayurveda Hospital, Jamnagar, Gujarat, were registered in this Randomised Parallel Group Clinical Trial. A prior written informed consent was taken from each and every patient. Clinical study was started after getting clearance from Institutional Ethics Committee (No. PGT/7/-A/Ethics/2013--2014/1767) and study was also registered under Clinical Trial Registry of India (CTRI/2014/01/004357).

Inclusion criteria {#sec2-1}
------------------

Patients of both sexes who met the diagnostic standards of *Timira*/immature cataract aged 30--60 years were included in this study. Participants were included on the basis symptoms like blurring of vision, visualization of nonexisting things, difficulty in bright light and dim light or night vision and signs like distant visual acuity, pinhole vision, best corrected visual acuity and cataract grading on slit lamp biomicroscopy according to Lenticular Opacity Classification System II.\[[@ref10]\]

Exclusion criteria {#sec2-2}
------------------

Patients who are suffering from congenital cataract, mature and hyper mature cataract, glaucoma, diabetic retinopathy, macular degeneration, retinitis pigmentosa, whose random blood sugar level and blood pressure are not within normal limits, who are under steroid treatment and or any kind of immunosuppressive therapy or under any cataract-inducing medication are excluded.

Grouping and posology {#sec2-3}
---------------------

All the registered patients were randomly assigned to two groups Group A and Group B (*n* = 20 each). Lottery method was adopted for randomization.

Group A: *Triphaladi Ghana Vati* (500 mg) orally administered twice daily for 3 monthsGroup B: *Elaneer Kuzhambu Anjana* used as *Anjana*, 60 mg in both eyes for topical use and *Triphaladi Ghana Vati* (500 mg) orally administered twice daily for 3 months.

Follow-up period was fixed as 1 month for both the groups.

The ingredients of *Triphaladi Ghana Vati* \[[Table 1](#T1){ref-type="table"}\] were procured from the Pharmacy, Gujarat Ayurved University, Jamnagar and *Ghana-Vati* was prepared. *Elaneer Kuzhambu Anjana* was procured from Arya Vaidya Shala, Kottakkal, Kerala (Batch no. 164292; Mfg. Jan 2014).

###### 

Ingredients of *Triphaladi Ghana Vati*

![](AYU-36-283-g001)

Criteria for assessment {#sec2-4}
-----------------------

Subjective parameters visual disturbances were assessed by Snellen\'s chart and Jaeger\'s chart reading. Blurring of vision, polyopia, nyctalopia, hamarlopia, glaring of light, colored halos, visualization of nonexisting things\[[@ref11]\] were assessed with the help of grading patternObjective parameters were obtained by retinoscopy, slit lamp bio microscopic examination in tangentional sectioning of lens and retro-illumination technique for grading of cataract, according to Lenticular Opacity Classification System II \[[Figure 1](#F1){ref-type="fig"}\] and direct and indirect ophthalmoscopic examinations were used to obtain values of objective parameters.

![The Lens Opacity Classification System II photographic grading standards. N: Nuclear photographs, C: Cortical photographs, P: Posterior subcapsular photographs](AYU-36-283-g002){#F1}

***Blurred vision:***

0 -- Absent

1 -- Mild

2 -- Moderate

3 -- Severe disturbing day to day life

***Visualization of nonexisting things like dots, lines, threads, etc:***

0 -- Absent

1 -- Occasional perception

2 -- Perception without disturbing routine work

3 -- Severe disturbing day to day work.

***Difficulty in day vision or vision in light, glare etc:***

0 -- No difficulty in light/day time

1 -- Slight difficulty in light/day time

2 -- Moderate difficulty in light/day time

3 -- Severe difficulty in light/day time.

***Difficult in night vision or dim light:***

0 -- No difficulty in night time

1 -- Slight difficulty in night time

2 -- Moderate difficulty in night time

3 -- Severe difficulty in night time.

***Unaided distant visual acuity, pinhole vision best corrected distant visual acuity (Snellen\'s distant vision chart)***

6/6-0

6/9-1

6/12-2

6/18-3

6/24-4

6/36-5

6/60-6.

Nuclear cataract Lenticular Opacity Classification System II \[[Figure 1](#F1){ref-type="fig"}\].

Statistical analysis {#sec2-5}
--------------------

Wilcoxon matched-pair signed-rank test and paired *t*-test were used to assess results for individual groups. Unpaired *t*-test and Fisher\'s exact test were used to calculate the comparison of results between the groups using GraphPad Instat 3.1 software (GraphPad Software Inc., California, USA).

Observations and Results {#sec1-3}
========================

Total 36 patients completed the treatment course. Three dropouts were there in Group A and one in Group B. In Group A, three patients discontinued the treatment, two patients thought that eye diseases have to be treated with eye drops. When this group did not receive any eye drops, they dropped out and one patient was transferred to other state. In Group B, one patient dropped out the treatment as he had to undergo cataract surgery.

There was statistically significant improvement in blurring of vision and in difficulty in light, day vision, glare was found in both the groups. In addition to that Group B showed statistically significant change in visualization of nonexisting things like dots, lines, threads, etc., and difficulty in night vision or dim vision was observed \[[Table 2](#T2){ref-type="table"}\].

###### 

Effect of treatment on symptoms of cataract (Wilcoxon matched-pairs signed-ranks test)

![](AYU-36-283-g003)

Statistically significant improvement in unaided distant visual acuity, pinhole vision, and in best-corrected vision was found in both the groups. Groups B also showed statistically significant reduction in nuclear cataract \[[Table 3](#T3){ref-type="table"}\].

###### 

Effect of treatment on signs of cataract (paired' *t*-test)

![](AYU-36-283-g004)

Comparison between Group A and B {#sec2-6}
--------------------------------

Statistically insignificant change assessed on comparison of difference between Group A and B with Fisher\'s exact test on symptoms such as blurred vision, visualization of nonexisting things and difficulty in light, day vision, glare, etc., Statistically significant change assessed on comparison between Group A and B with Fisher\'s exact test for difficulty in night vision or dim light \[[Table 4](#T4){ref-type="table"}\].

###### 

Comparison of difference of symptoms between Group A and B (Fisher\'s exact test)

![](AYU-36-283-g005)

Statistically insignificant change was assessed on comparison between Group A and Group B with unpaired *t*-test on signs such as unaided distant visual acuity, pinhole vision and best-corrected vision. Statistically significant change was observed on comparison between Group A and B with unpaired *t*-test for nuclear cataract \[[Table 5](#T5){ref-type="table"}\].

###### 

Comparison of difference of signs between Group A and B (unpaired *t*-test)

![](AYU-36-283-g006)

Out of 36 patients in Group A 52.94% patients showed mild improvement, 23.53% remained unchanged, moderate improvements was found in 17.65% and 5.88% showed marked improvement and no patient was cured 0%. In Group B 47.36% patients showed moderate improvement, 26.32% showed marked and mild improvement, respectively, and no patient was cured or remained unchanged \[[Figure 2](#F2){ref-type="fig"}\].

![Overall effect of therapy](AYU-36-283-g007){#F2}

Discussion {#sec1-4}
==========

Findings of both the groups suggest that selected drugs are effective, but better results were observed in Group B where both the drugs were administered to the patients. This can be because administration of oral drug alone is not sufficient to reverse the biochemical changes happening in the whole body and to attain sufficient quantity of drug to ocular tissues. Hence, a combination of oral and local administration is a must. *Anjana* type of ocular drug administration keeps the drug in contact with the eye surface longer. This *Kriya Kalpa* was an everyday routine to Indians which prevented refractive errors and cataract. *Anjana* is an excellent *Kalpana* which gives excellent systemic results, is evident from experimental and clinical study. In this way, *Elaneer Kuzhambu Anjana* can arrest, delay or reverse progression of cataract.\[[@ref12]\]

In the present study, test drug contained the ingredients suspended in tender coconut water, which is akin to plasma concentrate thus facilitating drug absorption by ocular tissue which also enters the systemic circulation. Also, the nutritive elements in coconut water media can nourish the lens, arresting degenerative changes and promoting lens nutrition, thus reversing nuclear cataract.

This drug is having all the 6 *Rasas* viz. *Madhura* (sweet), *Amla* (sour), *Lavana* (salty), *Katu* (pungent), *Tikta* (bitter) and *Kashaya* (astringent); *Laghu* (light), *Ruksha* (dry), *Sheeta* (cold), *Snigdha* (unctous) and *Teekshna Gunas* (properties); *Ushna* and *Sheeta Veerya Dravya*; *Lekhana* (scrapping), *Chhedaniya*, *Shodhana* (purifying), *Rasayana*, *Chakshushya* and *Tridosha Shamaka* properties. *Katu Rasa* is having *Ushna*, *Pachana* (digestive), *Kaphahara* properties. *Kledopashoshana* (dries up moisture), *Shlesmopashoshana* properties are possessed by *Tikta Rasa*. *Kashaya Rasa* shows its *Shoshana* (absorbing), more particularly *Kledashoshana* and *Shleshma Prashamana* properties. *Laghu Guna* has *Kaphahara* properties, *Lekhana* property is being possessed by *Tikta* and *Kashaya Rasa* and *Laghu Guna*. *Tikta Rasa* shows its *Chhedaniya* property, *Katu Rasa* is *Teekshna* and possessing *Marga Vivarana* (expand/dilate channels) action. Because of the above said inherent properties of drug, after getting absorbed, it may scrap away the vitiated *Kapha*, *Ama* and *Meda* already lodged in the *Patalas*, *Rupavaha Sira* as well as in *Drishti*. Their *Shuddha Srotasa* (opened channels) allows free movement of *Vata*, *Pitta* and *Pitta* performs its normal function of visual perception which was previously experiencing hindrance due to vitiated *Kapha*. The specific activity like *Kaphahara* and *Pittavardhaka* make an overall attempt to enhance the qualities of *Tarpaka Kapha* and *Alochaka Pitta* by alleviating the disturbances related to them.\[[@ref8]\]

Senile cataract or *Timira* is a *Swabhava Balapravritta Vyadhi* which occurs by natural ageing process. Taking *Rasayana* is helpful to increase the immunity of person to keep him away from diseases which influence the fundamental aspect of body viz. *Dhatus*, *Agni* and *Srotamsi* and *Ojas* etc., Characteristic properties of polyherbal formulation *Triphaladi Ghana Vati* which can help in preventing, delaying and reversal of senile cataract are as follows-

*Triphala* that is *Amalaki* (*Emblica officinalis* Linn.), *Haritaki* (*Terminalia chebula* Retz.), and *Vibheetaki* (*Terminalia bellirica* Roxb.) is having adaptogenic, antioxidant, anti-cataract, immunomodulatory, anti-diabetic, anti-hypercholesterolemic,\[[@ref13]\] free radical scavenger and rejuvenation properties.\[[@ref14]\] *Tulasi* (*Ocimum sanctum* Linn.) is having adaptogenic, antioxidant, anti-cataract, immunomodulatory, anti-diabetic, anti-hypercholesterolemic, free radical scavenger\[[@ref15]\] and advanced glycation end products-inhibitor properties.\[[@ref16]\] *Guduchi* (*Tinospora cordifolia* Miers.) is a adaptogenic,\[[@ref17]\] anti-oxidant,\[[@ref18]\] free radical scavenger, anti-cataract,\[[@ref19]\] immunomodulatory, anti-diabetic, anti-hypercholesterolemic and rejuvenating drug.\[[@ref20]\] *Haridra* (*Curcuma longa* Linn.) is having anti-oxidant,\[[@ref21]\] free radical scavenger,\[[@ref22]\] anti-diabetic, anti-age\[[@ref23]\] anti hypercholesterolemic,\[[@ref24]\] adaptogenic\[[@ref25]\] characteristics. *Daruharidra* (*Berberis aristata* DC.) is having anti-diabetic, anti-hyperlipidemia, anti-oxidant,\[[@ref26]\] anti-inflammatory specially in ocular infections, eye infections,\[[@ref27]\] adaptogenic,\[[@ref28]\] immunomodulatory,\[[@ref29]\] anti-cataract\[[@ref30]\] effect. *Shunthi* (*Zingiber officinale* Rosc.) is having advanced glycation end products-inhibitor,\[[@ref17]\] immunomodulatory,\[[@ref29]\] anti-diabetic, anti-hyperlipidemia, anti-oxidant,\[[@ref31]\] anti-ageing,\[[@ref32]\] immunomodulatory, anti-cataract, free radical scavenger\[[@ref33]\] properties. *Yashtimadhu* (*Glycyrrhiza glabra* Linn.) is having antioxidant,\[[@ref32]\] immunomodulatory activity,\[[@ref34]\] anti-diabetic, *Rasayana*,\[[@ref35]\] anti-hypercholesterolemic,\[[@ref36]\] enhancer of the bio-availability of drugs\[[@ref37]\] like actions. *Punarnava* (*Boerhavia diffusa* Linn.) is having immunomodulatory,\[[@ref29]\] antioxidant,\[[@ref38]\] antihypercholesterolemic, potential nutrients source,\[[@ref39]\] adaptogenic, immunopotentiating,\[[@ref40]\] *Rasayana*\[[@ref41]\] like actions. *Gokshura* (*Tribulus terrestris* Linn.) is having immunomodulatory, anti-diabetic, hypolipidemic,\[[@ref42]\] adaptogenic, *Rasayana*,\[[@ref43]\] antioxidant\[[@ref44]\] and anti-cataract\[[@ref45]\] properties. Maximum numbers of ingredients of *Triphaladi Ghana Vati* are having *Rasayana* or rejuvenating, adaptogenic, immunomodulatory, anti-diabetic and anti-cataract effect. These properties are beneficial in senile cataract.

In Ayurvedic classical texts administration of potent psycho-physical rejuvenator formulations come under *Rasayana Chikitsa* which frees one off the diseases, improves quality of life and delays senile degenerative changes and have *Chakshushya* properties that is beneficial to eye.\[[@ref46]\] Cataract is also an ageing disorder and possible move to delay/arrest these senile changes is to start *Rasayana Chikitsa* as early as possible. *Chakshushya Rasayana* is the best choice to delay cataract changes. Hence, *Triphaladi Ghana Vati* can arrest, delay, or reverse progression of cataract.

Multicentric studies with larger sample size on same drugs should be carried out to bring authenticity of results. Photo documented studies are a must so that we can demonstrate the improvement in signs. Protocol of treatment for different types of cataract with choice of drugs based on *Doshas* must be tried. Effect of test drugs on different morphological cataracts needs to be done.

As, till date no medical treatment is available for cataract if the test drugs prove to have anti-cataract effect, then this can reduce a lot of financial burden on patients and can be a milestone in improving healthcare system. For better recording of cataract grading a good quality photographic attachment on slit lamp biomicroscope will add great value to the objectivity and reproducibility of the result as in this study researcher found this as a limitation of the study.

Conclusion {#sec1-5}
==========

Internal use of *Triphaladi Ghana Vati* along with *Anjana* with *Elaneer Kuzhambu Anjana* that is combined therapy in Group B showed better results. This can be concluded that both systemic and topical administration is required for better management of *Timira* (senile cataract). *Chakshushya Rasayana*, *Chakshushya Ahara Vihara*, early diagnosis and proper management on *Doshic* lines can prevent arrest or delay senile cataract. The clinical study establishes both the test drugs can reduce and control the progress of *Timira*/cataract.
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